Pharmacogenetics Overview of Quetiapine for Mental Health Disorders

Syifa Khaira; Shofura Marsa Qolbina; Melisa Intan Barliana; Neily Zakiyah

doi:10.24198/farmaka.v22i2.55219

Pharmacogenetics Overview of Quetiapine for Mental Health Disorders

Syifa Khaira, Shofura Marsa Qolbina, Melisa Intan Barliana, Neily Zakiyah

Abstrak

Severe mental health disorders, such as schizophrenia and bipolar, often require treatment with atypical antipsychotic drugs, yet many patients exhibit incomplete responsiveness and adverse effects. This has led to the exploration of pharmacogenetics to personalize treatment potentially. Quetiapine, a commonly used atypical antipsychotic, is often used in mental health disorders for depressive episodes. Its pharmacokinetics and pharmacodynamics are potentially influenced by genetic variations in Cytochrome P450 (CYP) enzymes, Dopamine receptor D3 (DRD3), and other genes. Previous studies investigated the impact of genetic variants on quetiapine metabolism, revealing possible associations with CYP2D6, CYP2C19, Catechol-O-methyltransferase (COMT), and other genes. Notably, the COMT variant rs13306278 was linked to increased quetiapine exposure. CYP3A5 and CYP2B6 phenotypes also affected quetiapine variability, with the ATP-binding cassette super-family G member 2 (ABCG2) variant rs2231142 associated with quetiapine accumulation. Recent pharmacogenetic advancements emphasize individualized treatment based on genetic profiles, particularly considering interactions with CYP3A4. Although concerns exist regarding drug-drug interactions and limited efficacy in certain conditions, integrating genetic information into clinical practice holds promise for optimizing quetiapine therapy and improving patient outcomes.

Teks Lengkap:

PDF (English)

Referensi

Arvanitis, L. A., & Miller, B. G. (1997). Multiple fixed doses of “seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry, 42(4), 233–246. https://doi.org/10.1016/S0006-3223(97)00190-X

Ayano, G. (2016). Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 2D6 Enzyme and Relevant Drug Interactions. Clinical Pharmacology & Biopharmaceutics 2016 5:4, 5(4), 1–4. https://doi.org/10.4172/2167-065X.1000162

Bakken, G. V., Molden, E., & Hermann, M. (2015). Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients. Therapeutic Drug Monitoring, 37(2), 256–261.

https://doi.org/10.1097/FTD.0000000000000135

Basile, V. S., Masellis, M., Potkin, S. G., & Kennedy, J. L. (2002). Pharmacogenomics in schizophrenia: the quest for individualized therapy. Human molecular genetics, 11(20), 2517–2530. https://doi.org/10.1093/hmg/11.20.251

Beunk, L., Nijenhuis, M., Soree, B., de Boer-Veger, N. J., Buunk, A. M., Guchelaar, H. J., Houwink, E. J. F., Risselada, A., Rongen, G. A. P. J. M., van Schaik, R. H. N., Swen, J. J., Touw, D., van Westrhenen, R., Deneer, V. H. M., & van der Weide, J. (2023). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. European Journal of Human Genetics 2023 32:3, 32(3), 278–285. https://doi.org/10.1038/s41431-023-01347-3

Borison, R. L., Arvanitis, L. A., & Miller, B. G. (1996). ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. Journal of Clinical Psychopharmacology, 16(2), 158-169.

Cabaleiro, T., López-Rodríguez, R., Román, M., Ochoa, D., Novalbos, J., Borobia, A., Carcas, A., & Abad-Santos, F. (2015). Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. International Clinical Psychopharmacology, 30(2), 82–88. https://doi.org/10.1097/YIC.0000000000000047

Correll, C. U., & Schooler, N. R. (2020). Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatric Disease and Treatment, 16, 519-534. https://doi.org/10.2147/NDT.S225643

DeVane, C. L., & Nemeroff, C. B. (2001). Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clinical Pharmacokinetics, 40(7), 509–522. https://doi.org/10.2165/00003088-200140070-00003/METRICS

Friedman, J. H., Bishnoi, I. R., Perel, J. M., & Henkel, J. (1997). Quetiapine: A new atypical antipsychotic drug. Journal of Clinical Psychopharmacology, 17(3), 190-197.

Gajwani, P., Muzina, D. J., Kemp, D. E., Gao, K., & Calabrese, J. R. (2007). Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies. Neuropsychiatric disease and treatment, 3(6), 847–853. https://doi.org/10.2147/ndt.s1636

Hardoy, M. C., Garofalo, A., Carpiniello, B., Calabrese, J. R., & Carta, M. G. (2005). Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder. Clinical Practice and Epidemiology in Mental Health : CP & EMH, 1(7), 7. https://doi.org/10.1186/1745-0179-1-7

Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., ... & Insel, T. R. (2015). Schizophrenia. Nature Reviews Disease Primers, 1(1), 1-23. https://doi.org/10.1038/nrdp.2015.67

Kanba, S., Murasaki, M., Koyama, T., & et al. (2019). Long-term mood/antidepressant effects of quetiapine extended-release formulation: An open-label, non-controlled extension study in Japanese patients with bipolar depression. BMC Psychiatry, 19, 198. https://doi.org/10.1186/s12888-019-2181-9

LaLonde, C. D., & Van Lieshout, R. J. (2011). Treating generalized anxiety disorder with second generation antipsychotics: A systematic review and meta-analysis. Journal of Clinical Psychopharmacology, 31(3), 326–333. https://doi.org/10.1097/JCP.0B013E31821B2B3F

Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., ... & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962. https://doi.org/10.1016/S0140-6736(13)60733-3

Muñoz-Berbel, X., & Panov Panov, G. (2022). Early Markers in Resistant Schizophrenia: Effect of the First Antipsychotic Drug. Diagnostics 2022, Vol. 12, Page 803, 12(4), 803. https://doi.org/10.3390/DIAGNOSTICS12040803

Mutiara, M. (2017). Penerapan Terapi Suportif untuk Meningkatkan Manajemen Emosi Negatif pada Individu yang Memiliki Pasangan Skizofrenia. Jurnal Muara Ilmu Sosial, Humaniora, Dan Seni, 1(1), 105. https://doi.org/10.24912/jmishumsen.v1i1.340

Pardede, S. (2017). Penerapan terapi suportif dengan teknik bimbingan untuk mengurangi dorongan bunuh diri pada pasien skizofrenia. TERAPUTIK: Jurnal Bimbingan Dan Konseling, 1(1), 89. https://doi.org/10.26539/117

Pombaile, N. P. Z., & Hidayati, L. N. (2023). Penerapan Terapi Berkenalan Dalam Mengatasi Gejala Isolasi Sosial Pada Pasien Skizofrenia: Studi Kasus. JKJ): Persatuan Perawat Nasional Indonesia, 11(2), 333–345.

Riedel, M., Müller, N., Stradding, M., Spellmann, I., Severus, E., & Möller, H. J. (2007). Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease and Treatment, 3(2), 219. https://doi.org/10.2147/NEDT.2007.3.2.219

Suppes, T., Vieta, E., Liu, S., Brecher, M., & Paulsson, B. (2009). Maintenance treatment for patients with bipolar I disorder: Results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). American Journal of Psychiatry, 166(4), 476–488. https://doi.org/10.1176/APPI.AJP.2008.08020189/ASSET/IMAGES/LARGE/U316T4.JPEG

Valentine, M. J., Kayastha, A., Newsome-Cuby, T. R., Nguyen, A. T. N., Fisher, R. G., Pham, H. M., Meimon, S. A., Phu, A., Parry, C. A., Nelson, J. J., Hayes, E. C., & Muranjan, S. (2024). A Clinical Suspicion of Quetiapine-Induced Psychosis: A Case Report and Literature Review. Cureus, 16(1). https://doi.org/10.7759/CUREUS.52167

Ortega-Ruiz, M., Soria-Chacartegui, P., Villapalos-García, G., Abad-Santos, F., & Zubiaur, P. (2022). The Pharmacogenetics of Treatment with Quetiapine. Future Pharmacology 2022, Vol. 2, Pages 276-286, 2(3), 276–286. https://doi.org/10.3390/FUTUREPHARMACOL2030018

Peuskens, J., & Link, C. G. (1997). A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta psychiatrica Scandinavica, 96(4), 265–273. https://doi.org/10.1111/j.1600-0447.1997.tb10162.x

Potkin, S. G., Preskorn, S., Hochfeld, M., & Meng, X. (2013). A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. Journal of Clinical Psychopharmacology, 33(1), 3–10. https://doi.org/10.1097/JCP.0B013E31827C0314

Poyurovsky, M., & Weizman, A. (2021). Quetiapine for bipolar depressive episode in obsessive-compulsive disorder patients maintained on selective serotonin reuptake inhibitor treatment. Clinical Neuropharmacology, 44(4), 123–125. https://doi.org/10.1097/WNF.0000000000000456

Rudå, D., Jensen, K. G., Decara, M. S., Klauber, D. G., Fagerlund, B., Møllegaard, J. R., Linnet, K., Werge, T., Correll, C. U., Fink-Jensen, A., Jürgens, G., & Pagsberg, A. K. (2021). CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis. Journal of Clinical Psychopharmacology, 41(6), 667–672. https://doi.org/10.1097/JCP.0000000000001490

Saiz-Rodríguez, M., Belmonte, C., Román, M., Ochoa, D., Jiang-Zheng, C., Koller, D., Mejía, G., Zubiaur, P., Wojnicz, A., & Abad-Santos, F. (2018). Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic & Clinical Pharmacology & Toxicology, 123(4), 474–485. https://doi.org/10.1111/BCPT.13031

Small, J. G., Hirsch, S. R., Arvanitis, L. A., Miller, B. G., & Link, C. G. (1997). Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Archives of general psychiatry, 54(6), 549–557. https://doi.org/10.1001/archpsyc.1997.01830180067009

Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010). Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophrenia Research, 122(1-3), 1-23. https://doi.org/10.1016/j.schres.2010.05.025

Tran, J., Gervase, M. A., Evans, J., Deville, R., & Dong, X. (2021). The stability of quetiapine oral suspension compounded from commercially available tablets. PLOS ONE, 16(8), e0255963. https://doi.org/10.1371/JOURNAL.PONE.0255963

Van Der Weide, K., & Van Der Weide, J. (2014). The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. Journal of Clinical Psychopharmacology, 34(2), 256–260. https://doi.org/10.1097/JCP.0000000000000070

Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., & Qin, S. (2021). Cytochrome P450 Enzymes and Drug Metabolism in Humans. International Journal of Molecular Sciences, 22(23). https://doi.org/10.3390/IJMS222312808

Zubiaur, P., Fernández-Campos, P., Navares-Gómez, M., Soria-Chacartegui, P., Villapalos-García, G., Román, M., Mejía-Abril, G., Ochoa, D., & Abad-Santos, F. (2021). Variants in comt, cyp3a5, cyp2b6, and abcg2 alterquetiapine pharmacokinetics. Pharmaceutics, 13(10), 1573. https://doi.org/10.3390/PHARMACEUTICS13101573/S1

DOI: https://doi.org/10.24198/farmaka.v22i2.55219

DOI (PDF (English)): https://doi.org/10.24198/farmaka.v22i2.55219.g23494